Cameron Brennan

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
    Edward R Kastenhuber
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Acta Neuropathol 127:747-59. 2014
  2. pmc The somatic genomic landscape of glioblastoma
    Cameron W Brennan
    Human Oncology and Pathogenesis Program, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, Department of Neurological Surgery, Weill Cornell Medical Center, New York, NY 10065, USA Electronic address
    Cell 155:462-77. 2013
  3. pmc Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development
    Ruprecht Wiedemeyer
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 13:355-64. 2008
  4. doi request reprint Genomic profiles of glioma
    Cameron Brennan
    Human Oncology and Pathogenesis Program, Department of Neurosurgery and The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Neurol Neurosci Rep 11:291-7. 2011
  5. pmc Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations
    Cameron Brennan
    Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    PLoS ONE 4:e7752. 2009
  6. ncbi request reprint Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities
    Elizabeth A Maher
    Center for Neuro Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 66:11502-13. 2006
  7. pmc Mig-6 controls EGFR trafficking and suppresses gliomagenesis
    Haoqiang Ying
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 107:6912-7. 2010
  8. pmc Integrative genome comparison of primary and metastatic melanomas
    Omar Kabbarah
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 5:e10770. 2010
  9. ncbi request reprint High-resolution global profiling of genomic alterations with long oligonucleotide microarray
    Cameron Brennan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 64:4744-8. 2004
  10. ncbi request reprint Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types
    Eric S Martin
    Department of Medical Oncology, Belfer Institute for Innovative Cancer Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 67:10736-43. 2007

Detail Information

Publications43

  1. pmc Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
    Edward R Kastenhuber
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Acta Neuropathol 127:747-59. 2014
    ..To this end, we demonstrate the performance of the Nanostring assay in RNA derived from routinely collected formalin-fixed paraffin-embedded tissue...
  2. pmc The somatic genomic landscape of glioblastoma
    Cameron W Brennan
    Human Oncology and Pathogenesis Program, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, Department of Neurological Surgery, Weill Cornell Medical Center, New York, NY 10065, USA Electronic address
    Cell 155:462-77. 2013
    ....
  3. pmc Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development
    Ruprecht Wiedemeyer
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 13:355-64. 2008
    ....
  4. doi request reprint Genomic profiles of glioma
    Cameron Brennan
    Human Oncology and Pathogenesis Program, Department of Neurosurgery and The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Neurol Neurosci Rep 11:291-7. 2011
    ..The analysis of this data is still in the early stage. Nonetheless, several preliminary findings merit consideration in the development and interpretation of current clinical trials...
  5. pmc Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations
    Cameron Brennan
    Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    PLoS ONE 4:e7752. 2009
    ..From a practical and therapeutic standpoint, classifying GBMs by signal transduction pathway activation and by mutation in pathway member genes may be particularly valuable for the development of targeted therapies...
  6. ncbi request reprint Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities
    Elizabeth A Maher
    Center for Neuro Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 66:11502-13. 2006
    ..We conclude that glioblastoma is composed of at least three distinct molecular subtypes, including novel subgroups of secondary glioblastoma, which may benefit from different therapeutic strategies...
  7. pmc Mig-6 controls EGFR trafficking and suppresses gliomagenesis
    Haoqiang Ying
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 107:6912-7. 2010
    ..In GBM, the highly frequent loss of Mig-6 would therefore serve to sustain aberrant EGFR-mediated oncogenic signaling. Together, these data uncover a unique tumor suppression mechanism involving the regulation of receptor trafficking...
  8. pmc Integrative genome comparison of primary and metastatic melanomas
    Omar Kabbarah
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 5:e10770. 2010
    ....
  9. ncbi request reprint High-resolution global profiling of genomic alterations with long oligonucleotide microarray
    Cameron Brennan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 64:4744-8. 2004
    ....
  10. ncbi request reprint Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types
    Eric S Martin
    Department of Medical Oncology, Belfer Institute for Innovative Cancer Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 67:10736-43. 2007
    ....
  11. pmc Identification of DOK genes as lung tumor suppressors
    Alice H Berger
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Nat Genet 42:216-23. 2010
    ..Given the genomic localization of DOK2, we propose it as an 8p21.3 haploinsufficient human lung tumor suppressor...
  12. pmc DNA amplification method tolerant to sample degradation
    Gang Wang
    Department of Radiation Oncology, and Arthur and Rochelle Belfer Cancer Genomics Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genome Res 14:2357-66. 2004
    ..99). The simplicity and universal applicability of RCA-RCA make it a powerful new tool for genome analysis with unique advantages over previous amplification technologies...
  13. pmc High-resolution genomic profiles of human lung cancer
    Giovanni Tonon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 102:9625-30. 2005
    ..Integrated DNA-RNA analyses identified WHSC1L1 and TPX2 as two candidates likely targeted for amplification in both pancreatic ductal adenocarcinoma and non-small-cell lung cancer...
  14. pmc PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas
    Hongwu Zheng
    Belfer Institute for Applied Cancer Science, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 17:497-509. 2010
    ..The identification of PLAGL2 as a glioma oncogene highlights the importance of a growing class of cancer genes functioning to impart stem cell-like characteristics in malignant cells...
  15. ncbi request reprint Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene
    Minjung Kim
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cell 125:1269-81. 2006
    ..Thus, comparative oncogenomics has enabled the identification and facilitated the validation of a highly relevant cancer gene governing metastatic potential in human melanoma...
  16. pmc Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression
    Elena I Fomchenko
    Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 6:e20605. 2011
    ..Glioma progression is associated with elevated growth factor signaling and loss of function of tumor suppressors Ink4a, Arf and Pten. Yet, gliomas are cellularly heterogeneous; they recruit and trap normal cells during infiltration...
  17. doi request reprint A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases
    Cameron Brennan
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York
    Int J Radiat Oncol Biol Phys 88:130-6. 2014
    ..To evaluate local control after surgical resection and postoperative stereotactic radiosurgery (SRS) for brain metastases...
  18. pmc microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma
    Giannicola Genovese
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Discov 2:736-49. 2012
    ....
  19. pmc The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation
    Igor Vivanco
    Memorial Sloan Kettering Cancer Center, New York, NY 10021
    Proc Natl Acad Sci U S A 107:6459-64. 2010
    ..Our study identifies a critical role for PTEN in EGFR signal termination and suggests that more potent EGFR inhibition should overcome resistance caused by PI3K pathway activation...
  20. pmc p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
    Hongwu Zheng
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 455:1129-33. 2008
    ....
  21. pmc MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    James Bean
    Human Oncology and Pathogenesis Program, Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:20932-7. 2007
    ..Taken together, these data suggest that MET amplification occurs independently of EGFR(T790M) mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib...
  22. ncbi request reprint High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
    Daniel R Carrasco
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Cell 9:313-25. 2006
    ....
  23. pmc Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse
    Nabeel Bardeesy
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:5947-52. 2006
    ....
  24. pmc Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine
    Sevin Turcan
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncotarget 4:1729-36. 2013
    ..These findings have substantial impact for exploring new treatment strategies for patients with IDH mutant gliomas. ..
  25. pmc Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor
    Alexander H Stegh
    Belfer Institute for Applied Cancer Science, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Genes Dev 24:2194-204. 2010
    ..Thus, Bcl2L12 is a multifunctional protein that contributes to intense therapeutic resistance of GBM through its ability to operate on two key nodes of cytoplasmic and nuclear signaling cascades...
  26. pmc High-resolution characterization of the pancreatic adenocarcinoma genome
    Andrew J Aguirre
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:9067-72. 2004
    ..Thus, the integration of DNA and RNA profiles provides a highly productive entry point for the discovery of genes involved in the pathogenesis of pancreatic adenocarcinoma...
  27. ncbi request reprint Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression
    Jun Yao
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 66:4065-78. 2006
    ..These results show the power of combined array CGH and SAGE analysis for the identification of candidate amplicon targets and identify H2AFJ and EPS8 as novel putative oncogenes in breast cancer...
  28. ncbi request reprint Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
    Jayne M Stommel
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Science 318:287-90. 2007
    ..Thus, effective GBM therapy may require combined regimens targeting multiple RTKs...
  29. pmc Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia
    Christoph P Hofstetter
    Department of Neurological Surgery, Weill Cornell Brain Tumor Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States of America
    PLoS ONE 7:e30059. 2012
    ..Recent evidence suggests that hypoxia induces protein phosphatase 2A (PP2A), a regulator of cell cycle and cell death. The effects of PP2A on GBM tumor cell proliferation and survival during hypoxic conditions have not been studied...
  30. pmc The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo
    Jason T Huse
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 23:1327-37. 2009
    ..Our results document a new epigenetic mechanism for PTEN regulation in glioma and further highlight dysregulation of Akt signaling as crucial to the development of these tumors...
  31. pmc Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers
    Richard S Maser
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 447:966-71. 2007
    ..The highly concordant nature of genomic events encourages the use of genomically unstable murine cancer models in the discovery of biological driver events in the human oncogenome...
  32. pmc Emerging insights into the molecular and cellular basis of glioblastoma
    Gavin P Dunn
    Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Genes Dev 26:756-84. 2012
    ..These studies provide the emerging view that "glioblastoma" represents several histologically similar yet molecularly heterogeneous diseases, which influences taxonomic classification systems, prognosis, and therapeutic decisions...
  33. ncbi request reprint A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma
    Fenghua Liu
    Department of Neurological Surgery, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Cancer Res 66:10815-23. 2006
    ..This novel genome-wide approach greatly expanded the list of target genes in glioblastoma and represents a powerful new strategy to identify the upstream determinants of tumor phenotype in a range of human cancers...
  34. doi request reprint Glioblastoma stem-like cells give rise to tumour endothelium
    Rong Wang
    Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 468:829-33. 2010
    ....
  35. pmc Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis
    Lauren T McGillicuddy
    Genetics Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 16:44-54. 2009
    ....
  36. pmc The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
    Selvaraju Veeriah
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 106:9435-40. 2009
    ..PTPRD was found to dephosphorylate the oncoprotein STAT3. These results implicate PTPRD as a tumor suppressor on chromosome 9p that is involved in the development of GBMs and multiple human cancers...
  37. ncbi request reprint Magnetic resonance spectroscopy imaging in radiotherapy planning for recurrent glioma
    Ase M Ballangrud
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Phys 38:2724-30. 2011
    ..The purpose of this study was to investigate how incorporation of magnetic resonance spectroscopy imaging (MRSI) into radiotherapy planning would increase the target volume for patients with recurrent glioma...
  38. pmc Balanced-PCR amplification allows unbiased identification of genomic copy changes in minute cell and tissue samples
    Gang Wang
    Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Nucleic Acids Res 32:e76. 2004
    ..Balanced-PCR allows amplification and recovery of modestly degraded genomic DNA for subsequent retrospective analysis of human tumors with known outcomes...
  39. ncbi request reprint Molecular characterization of the tumor microenvironment in breast cancer
    Minna Allinen
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Cell 6:17-32. 2004
    ..Thus, chemokines may play a role in breast tumorigenesis by acting as paracrine factors...
  40. pmc Molecular diversity of astrocytes with implications for neurological disorders
    Robert M Bachoo
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:8384-9. 2004
    ....
  41. ncbi request reprint Advanced imaging in brain tumor surgery
    Robert J Young
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Neuroimaging Clin N Am 20:311-35. 2010
    ....
  42. ncbi request reprint Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases
    Ashwatha Narayana
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
    Stereotact Funct Neurosurg 85:82-7. 2007
    ....
  43. doi request reprint Presurgical evaluation of language using functional magnetic resonance imaging in brain tumor patients with previous surgery
    Kyung K Peck
    Department of Radiology and Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neurosurgery 64:644-52; discussion 652-3. 2009
    ....